Can post-neoadjuvant therapy molecular classification guide future treatment selection for muscle-invasive bladder cancer?

David J. VanderWeele, Joshua J Meeks, Maha Hussain

Research output: Contribution to journalEditorial

Original languageEnglish (US)
Pages (from-to)S91-S92
JournalTranslational Andrology and Urology
Volume8
DOIs
StatePublished - Jan 1 2019

Fingerprint

Neoadjuvant Therapy
Urinary Bladder Neoplasms
Muscles
Therapeutics

ASJC Scopus subject areas

  • Reproductive Medicine
  • Urology

Cite this

@article{7d060ad66f924ce5853028352de07527,
title = "Can post-neoadjuvant therapy molecular classification guide future treatment selection for muscle-invasive bladder cancer?",
author = "VanderWeele, {David J.} and Meeks, {Joshua J} and Maha Hussain",
year = "2019",
month = "1",
day = "1",
doi = "10.21037/tau.2018.12.07",
language = "English (US)",
volume = "8",
pages = "S91--S92",
journal = "Translational Andrology and Urology",
issn = "2223-4683",
publisher = "AME Publishing Company",

}

TY - JOUR

T1 - Can post-neoadjuvant therapy molecular classification guide future treatment selection for muscle-invasive bladder cancer?

AU - VanderWeele, David J.

AU - Meeks, Joshua J

AU - Hussain, Maha

PY - 2019/1/1

Y1 - 2019/1/1

UR - http://www.scopus.com/inward/record.url?scp=85068251170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068251170&partnerID=8YFLogxK

U2 - 10.21037/tau.2018.12.07

DO - 10.21037/tau.2018.12.07

M3 - Editorial

C2 - 31143677

AN - SCOPUS:85068251170

VL - 8

SP - S91-S92

JO - Translational Andrology and Urology

JF - Translational Andrology and Urology

SN - 2223-4683

ER -